The Cost of Menopause: From Data to Action

Economic Burden Unveiled

Menopause has emerged as a pressing economic issue in the UK, with symptoms like hot flashes, sleep disturbances, and cognitive fog driving significant workforce disruptions. A 2025 NHS Confederation study estimates that severe period pain and menopause-related conditions cost the economy nearly £11 billion yearly in absenteeism alone. This figure underscores how untreated symptoms lead to reduced hours, early retirements, and missed promotions, particularly among women aged 45-55—the fastest-growing segment of the labor force.

Recent shifts amplify the urgency. The Labour government's 2025 Employment Rights Act introduces mandatory Menopause Action Plans for firms with over 250 employees, effective from 2026 voluntarily and 2027 mandatorily. This responds to data showing 60,000 women unemployed due to symptoms, with direct economic impacts of £1.5 billion annually. Globally, lost productivity from menopause tops $150 billion, but UK-specific pressures, including NHS waiting lists for gynaecology services at 586,000 incomplete pathways as of December 2024, push more women toward costly private care, averaging £500 out-of-pocket.

Impacts ripple across stakeholders. Employers face higher turnover and training costs, while women endure pension shortfalls—exacerbated by a gender gap where menopause hits peak earning years. A 2025 Stanford study highlights a 'menopause penalty' with lasting earnings drops, and UK surveys indicate 18% of affected women consider quitting. Risks of inaction include widened health disparities, as women's conditions receive only 6% of health funding despite causing 75 million lost healthy life years globally each year.

Tensions arise in treatment approaches. A February 2026 BMJ study links menopausal hormone therapy (MHT) to reduced mortality, especially post-oophorectomy, countering two-decade declines in usage due to outdated safety fears. Yet, access barriers persist: the 2023 HRT prescription payment certificate saved £11 million for 500,000 women, but inequities favor those affording private options. Trade-offs include balancing workplace adjustments like flexible hours against potential stigma, where unsupportive environments have led to tripled tribunal claims citing menopause discrimination from 2022 to 2024.